A study in Diabetes Care showed that patients with type 2 diabetes on glyburide had lower rates of sudden cardiac arrest/ventricular arrhythmia, compared with those on glipizide. Researchers analyzed data from 1999 to 2010 US Medicaid claims involving 519,272 patients with diabetes using sulfonylureas and found that compared with glipizide, glimepiride had a propensity score-adjusted hazard ratio for sudden cardiac arrest/ventricular arrhythmia of 1.1.
Researchers compare safety of sulfonylureas as diabetes treatment
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.